DNA methylation level of OPCML and SFRP1: a potential diagnostic biomarker of cholangiocarcinoma

Tumor Biology

Volumn 36, Issue 7, 2015, Pages 4973-4978

  Amornpisutt, Rattaya ^a   Proungvitaya, Siriporn ^a,b   Jearanaikoon, Patcharee ^a,b   Limpaiboon, Temduang ^a,b  

^a KHON KAEN UNIVERSITY   (Thailand)

^b KHON KAEN UNIVERSITY   (Thailand)

Author keywords

Biliary tract cancer; Biomarkers; DNA methylation; Liver cancer; Methylation sensitive high resolution melting

Indexed keywords

BINDING PROTEIN; DNA; OPIOID BINDING PROTEIN CELL ADHESION MOLECULE LIKE PROTEIN; SECRETED FRIZZLED RELATED PROTEIN 1; TUMOR MARKER; UNCLASSIFIED DRUG; CELL ADHESION MOLECULE; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; MEMBRANE PROTEIN; OPCML PROTEIN, HUMAN; SFRP1 PROTEIN, HUMAN; SIGNAL PEPTIDE;

AREA UNDER THE CURVE; ARTICLE; BILE DUCT CARCINOMA; BILIARY TRACT BIOPSY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DNA METHYLATION; HIGH RESOLUTION MELTING ANALYSIS; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; OPCML GENE; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SFRP1 GENE; ANIMAL; BILIARY TRACT NEOPLASMS; CHOLANGIOCARCINOMA; DNA DENATURATION; FASCIOLA HEPATICA; GENETICS; PATHOLOGY;

ANIMALS; BILIARY TRACT NEOPLASMS; CELL ADHESION MOLECULES; CHOLANGIOCARCINOMA; DNA METHYLATION; FASCIOLA HEPATICA; GPI-LINKED PROTEINS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MEMBRANE PROTEINS; NUCLEIC ACID DENATURATION; ROC CURVE; TUMOR MARKERS, BIOLOGICAL;

EID: 84938212403     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-015-3147-2     Document Type: Article

References (33)

1. Gatto M, Bragazzi MC, Semeraro R, Napoli C, Gentile R, Torrice A, et al. Cholangiocarcinoma: update and future perspectives. Dig Liver Dis. 2010;42(4):253–60.
2. Mosconi S, Beretta GD, Labianca R, Zampino MG, Gatta G, Heinemann V. Cholangiocarcinoma. Crit Rev Oncol Hematol. 2009;69(3):259–70.
3. Sripa B, Brindley PJ, Mulvenna J, Laha T, Smout MJ, Mairiang E, et al. The tumorigenic liver fluke Opisthorchis viverrini–multiple pathways to cancer. Trends Parasitol. 2012;28(10):395–407.
4. Sripa B, Bethony JM, Sithithaworn P, Kaewkes S, Mairiang E, Loukas A, et al. Opisthorchiasis and Opisthorchis-associated cholangiocarcinoma in Thailand and Laos. Acta Trop. 2010;120 Suppl 1:S158–68.
5. Shin HR, Oh JK, Masuyer E, Curado MP, Bouvard V, Fang YY, et al. Epidemiology of cholangiocarcinoma: an update focusing on risk factors. Cancer Sci. 2010;101(3):579–85.
6. Sawanyawisuth K. Genes and cholangiocarcinoma. Southeast Asian J Trop Med Public Health. 2009;40(4):701–12.
7. Gatto M, Alvaro D. New insights on cholangiocarcinoma. World J Gastrointest Oncol. 2010;1(1):12–22.
8. Taby R, Issa JP. Cancer epigenetics. CA Cancer J Clin. 2010;60(6):376–92.
9. Duffy MJ, Napieralski R, Martens JW, Span PN, Spyratos F, Sweep FC, et al. Methylated genes as new cancer biomarkers. Eur J Cancer. 2009;45(3):335–46.
10. Duarte-Pereira S, Paiva F, Costa VL, Ramalho-Carvalho J, Savva-Bordalo J, Rodrigues A, et al. Prognostic value of opioid binding protein/cell adhesion molecule-like promoter methylation in bladder carcinoma. Eur J Cancer. 2011;47(7):1106–14.
11. Cui Y, Ying Y, van Hasselt A, Ng KM, Yu J, Zhang Q, et al. OPCML is a broad tumor suppressor for multiple carcinomas and lymphomas with frequently epigenetic inactivation. PLoS One. 2008;3(8):e2990.
12. Bombardelli L, Cavallaro U. Immunoglobulin-like cell adhesion molecules: novel signaling players in epithelial ovarian cancer. Int J Biochem Cell Biol. 2010;42(5):590–4.
13. Sellar GC, Watt KP, Rabiasz GJ, Stronach EA, Li L, Miller EP, et al. OPCML at 11q25 is epigenetically inactivated and has tumor-suppressor function in epithelial ovarian cancer. Nat Genet. 2003;34(3):337–43.
14. Lu CY, Hsieh SY, Lu YJ, Wu CS, Chen LC, Lo SJ, et al. Aberrant DNA methylation profile and frequent methylation of KLK10 and OXGR1 genes in hepatocellular carcinoma. Genes Chromosom Cancer. 2009;48(12):1057–68.
15. McKie AB, Vaughan S, Zanini E, Okon IS, Louis L, de Sousa C, et al. The OPCML tumor suppressor functions as a cell surface repressor-adaptor, negatively regulating receptor tyrosine kinases in epithelial ovarian cancer. Cancer Discov. 2012;2(2):156–71.
16. Zhang Y, Wang R, Song H, Huang G, Yi J, Zheng Y, et al. Methylation of multiple genes as a candidate biomarker in non-small cell lung cancer. Cancer Lett. 2011;303(1):21–8.
17. Esteve P, Bovolenta P. The advantages and disadvantages of sfrp1 and sfrp2 expression in pathological events. Tohoku J Exp Med. 2010;221(1):11–7.
18. Baylin SB, Ohm JE. Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction? Nat Rev Cancer. 2006;6(2):107–16.
19. Klarmann GJ, Decker A, Farrar WL. Epigenetic gene silencing in the Wnt pathway in breast cancer. Epigenetics. 2008;3(2):59–63.
20. Chung MT, Sytwu HK, Yan MD, Shih YL, Chang CC, Yu MH, et al. Promoter methylation of SFRPs gene family in cervical cancer. Gynecol Oncol. 2009;112(2):301–6.
21. Jiang GX, Liu W, Cui YF, Zhong XY, Tai S, Wang ZD, et al. Reconstitution of secreted frizzled-related protein 1 suppresses tumor growth and lung metastasis in an orthotopic model of hepatocellular carcinoma. Dig Dis Sci. 2010;55(10):2838–43.
22. Liu JB, Qiang FL, Dong J, Cai J, Zhou SH, Shi MX, et al. Plasma DNA methylation of Wnt antagonists predicts recurrence of esophageal squamous cell carcinoma. World J Gastroenterol. 2011;17(44):4917–21.
23. Rawson JB, Manno M, Mrkonjic M, Daftary D, Dicks E, Buchanan DD, et al. Promoter methylation of Wnt antagonists DKK1 and SFRP1 is associated with opposing tumor subtypes in two large populations of colorectal cancer patients. Carcinogenesis. 2011;32(5):741–7.
24. Saini S, Liu J, Yamamura S, Majid S, Kawakami K, Hirata H, et al. Functional significance of secreted Frizzled-related protein 1 in metastatic renal cell carcinomas. Cancer Res. 2009;69(17):6815–22.
25. Shen JZ, Xu CB, Fu HY, Wu DS, Zhou HR, Fan LP. Methylation of secreted frizzled related protein gene in acute leukemia patients in China. Asian Pac J Cancer Prev. 2011;12(10):2617–21.
26. Uhm KO, Lee ES, Lee YM, Kim HS, Park YN, Park SH. Aberrant promoter CpG islands methylation of tumor suppressor genes in cholangiocarcinoma. Oncol Res. 2008;17(4):151–7.
27. Sriraksa R, Zeller C, El-Bahrawy MA, Dai W, Daduang J, Jearanaikoon P, et al. CpG-island methylation study of liver fluke-related cholangiocarcinoma. Br J Cancer. 2011;104(8):1313–8.
28. Wojdacz TK, Dobrovic A. Methylation-sensitive high resolution melting (MS-HRM): a new approach for sensitive and high-throughput assessment of methylation. Nucleic Acids Res. 2007;35(6):e41.
29. Amornpisutt R, Sriraksa R, Limpaiboon T. Validation of methylation-sensitive high resolution melting for the detection of DNA methylation in cholangiocarcinoma. Clin Biochem. 2012;45(13–14):1092–4.
30. Sriraksa R, Chaopatchayakul P, Jearanaikoon P, Leelayuwat C, Limpaiboon T. Verification of complete bisulfite modification using Calponin-specific primer sets. Clin Biochem. 2010;43(4–5):528–30.
31. Harden SV, Guo Z, Epstein JI, Sidransky D. Quantitative GSTP1 methylation clearly distinguishes benign prostatic tissue and limited prostate adenocarcinoma. J Urol. 2003;169(3):1138–42.
32. Watanabe Y, Kim HS, Castoro RJ, Chung W, Estecio MR, Kondo K, et al. Sensitive and specific detection of early gastric cancer with DNA methylation analysis of gastric washes. Gastroenterology. 2009;136(7):2149–58.
33. Renard I, Joniau S, van Cleynenbreugel B, Collette C, Naome C, Vlassenbroeck I, et al. Identification and validation of the methylated TWIST1 and NID2 genes through real-time methylation-specific polymerase chain reaction assays for the noninvasive detection of primary bladder cancer in urine samples. Eur Urol. 2010;58(1):96–104.